Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck

Sentinel Lymph Node Clinical Trial

Official title:

Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck - A Multi-Institutional Prospective Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04664582
• Other study ID #: SLNB for SCC
• Status: Recruiting
• Phase: N/A
• Start date: November 26, 2020
• Est. completion date: December 30, 2023

Study information

• Verified date: April 2022
• Source: Jewish General Hospital
• Contact: Sena Turkdogan, MD
• Phone: 5147308461
• Email: sena.turkdogan[@]mail.mcgill.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Current guidelines in management of regional lymph node metastases for cSCC patients include surgical resection with or without adjuvant therapy as well as chemotherapy and interdisciplinary management; in advanced disease, supportive and palliative care is recommended. These guidelines also define the role of SLNB in management of high-risk cSCC as unclear and suggest further studies need to determine its utility and indications11.

Currently, routine practice of performing SLNB in cSCC varies across Quebec and within Canada. At many institutions, SLNB is not routinely performed on patients with cSCC. The current standard of treatment is to observe closely when a patient is deemed to have a high-risk cancer, and if they have clinical or radiological findings of lymphadenopathy, a formal surgical neck dissection is performed. Given the comorbidities and risks involved in treatment of regional lymph nodes in cSCC, the role of SLNB in cSCC patients needs further clarification. This multicentre prospective study aims to better clarify this role and formulate suggested criteria for its indications.

Description:

INTRODUCTION:

Cutaneous Squamous Cell Carcinoma (cSCC) is a malignant neoplasm that arises from epidermal keratinocytes. It is the second most commonly seen nonmelanoma skin cancer after basal cell carcinoma (BCC) and is one of the most common malignancies in the world. The annual incidence of nonmelanoma skin cancers exceed all other malignancies combined. It also has a predilection for the head and neck, due to being a common location for sun-exposed skin. While incidences of both BCC and squamous cell carcinoma are increasing worldwide, cSCC is increasing even more disproportionately. This increase in skin cancer trends is likely due to a combination of factors including increased sun exposure along with increasing life expectancies. Furthermore, unlike BCC which tends to have an indolent course and is rarely metastatic, cSCC has more metastatic potential than BCC. While the vast majority of cSCC cases can be treated with curative intent without complication, there are a certain subset of cSCC which behave aggressively with significant risk for local recurrence and distant metastasis.

Many retrospective studies have tried to define "high-risk" features in cSCC that are predictive of regional and distant metastasis or poor survival, including local recurrence, depth of invasion, larger size, perineural and lymphovascular invasion, poor differentiation, and immunosuppression. Despite this, there is poor concordance in current guidelines on which patient and tumor characteristics constitute high-risk features. These include discrepancies between major guiding associations, such as the American Joint Committee on Cancer and National Comprehensive Cancer Network Clinical Practice Guidelines. Ultimately, a consensus on the definition of high-risk features of cSCC is necessary in order to produce practical and precise guidelines to enhance patient care.

Sentinel Lymph Node Biopsy (SLNB) is an established prognostic procedure in determining the degree of spread of malignant cells. It is used widely in skin cancers such as melanoma, with consistent recommended guidelines by the American Society of Clinical Oncology (ASCO) and Society of Surgical Oncology (SSO). However, no such guideline currently exists for cSCC and recommendations for its routine use is conflicting in the literature. There exist many studies concerning the use of SLNB in cSCC, most of which are small and retrospective in nature.

Two systematic reviews on the subject both revealed that prospective studies documenting high-risk features were necessary. A meta-analysis that included 36 studies by Thompson et al. narrowed down tumor depth and tumor diameter as having the most significant risk ratio for recurrence, metastasis, and disease-specific death in cSCC respectively. However, they also concluded that unified, consistent collection and reporting of risk factors in a prospective, multicentered effort was needed. Lastly, a multi-institutional prospective study was performed by Mooney at al between 2010-2017. While the study was well designed, they only looked at 5 tumor characteristics, including tumor site, diameter, depth, differentiation and invasion. It also appears that they used a blue dye technique for SLNB over radioactive tracer methods preferred at other institutions. They conclude that significant predictors of metastasis were four or more high-risk features, which may be vague depending on which predictors the treating team is considering. Furthermore, the generalizability of the study may be limited due to including only Australian institutions. No prospective multi-institutional studies have looked at a North American patient population.

This prospective multicentre study aims to clarify the role of SLNB in cSCC by identifying patient and tumour characteristics for candidacy criteria in SLNB indication.

RATIONALE:

After the introduction of SLNB by Morton and Cochran in the 1990s, many studies and trials were run to determine its role and indications, particularly in melanoma. Three landmark trials, MSLT-I, DeCOG-SLT and MSLT-II, among other studies, lead to the creation of SLNB guidelines by ASCO and SSO for melanoma patients. SLNB has been shown to provide substantial prognostic information as well as possible therapeutic effects in some cases; whereas Completion Lymph Node Dissection (CLND) has been demonstrated not to provide any survival benefits.

Current guidelines in management of regional lymph node metastases for cSCC patients include surgical resection with or without adjuvant therapy as well as chemotherapy and interdisciplinary management; in advanced disease, supportive and palliative care is recommended. These guidelines also define the role of SLNB in management of high-risk cSCC as unclear and suggest further studies need to determine its utility and indications.

Currently, routine practice of performing SLNB in cSCC varies across Quebec and within Canada. At many institutions, SLNB is not routinely performed on patients with cSCC. The current standard of treatment is to observe closely when a patient is deemed to have a high-risk cancer, and if they have clinical or radiological findings of lymphadenopathy, a formal surgical neck dissection is performed. Given the comorbidities and risks involved in treatment of regional lymph nodes in cSCC, the role of SLNB in cSCC patients needs further clarification. This multicentre prospective study aims to better clarify this role and formulate suggested criteria for its indications.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: December 30, 2023
• Est. primary completion date: December 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria: high risk features rendering the patient eligible for SLNB in this study will include two or more of the following clinical or pathological features:

• Immunocompromised

• Size more than 2 cm

• Depth more than 6 mm

• Poorly differentiated histology

• Perineural invasion > 0.1mm

• Extensive lymphovascular invasion

Exclusion Criteria:

• Evidence of lymph node metastasis (clinical, radiological, or pathological)

• Previous surgery altering lymphatic drainage of the head and neck, such as a prior neck dissection or prior neck irradiation

• Pregnancy of breast-feeding

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Cutaneous Squamous Cell Carcinoma
• Sentinel Lymph Node
• Squamous Cell Carcinoma of Head and Neck

Intervention

Procedure:
• Sentinel Lymph Node Biopsy
see intervention group description

Locations

Country	Name	City	State
Canada	Jewish General Hospital	Montreal	Quebec

Sponsors (2)

Lead Sponsor	Collaborator
Jewish General Hospital	McGill University Health Centre/Research Institute of the McGill University Health Centre

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	predictive value of sentinel lymph node biopsy in cutaneous squamous cell carcinoma		1 month after feasibility recruitment completed (anticipated Dec 2021)
Secondary	disease free five year survival		5 years post intervention